Health Condition 1: M179- Osteoarthritis of knee, unspecified
Conditions
Interventions
Intervention1: Sulphasalazine
Duloxetine: Tab Sulphasalazine 30 mg/kg/day and Tab Duloxetine 40 mg/day in divided doses for 12 weeks.
Control Intervention1: Multivitamin
Duloxetine: Tab Multivitamin
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: Patient in chronic knee pain(pain more than 3 months) diagnosed as OA Knee of either grade I,II or III in accordance to kellgren Lawrence(KL) grading system 45 TO 80 years age, having ultrasound features of synovial hypertrophy will be included in our study.
Exclusion criteria
Exclusion criteria: Patients coexistent local or systemic inflammatory processes, OA knee grade (IV) history of inflammatory arthropathies or knee joint surgery, patients with hypersensitivity to sulfasalazine, its metabolite, sulfonamides, salicylates, or any component of the formulation, intestinal or urinary obstruction, and porphyria, will also be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoints of the study will be effusion-synovitis volume and VAS painTimepoint: 6 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Total dosage of analgesic requirement. 2) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Timepoint: 6 and 12 weeks | — |
Countries
India
Contacts
Public ContactGautam Das
Daradia the pain clinic
Outcome results
None listed